Coloplast A/S

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, Advanced Wound Dressings, and Biologics. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Voice and Respiratory Care segment refers to the sale of laryngectomy and tracheostomy products. The Interventional Urology segment includes the sale of urological products, including disposable products. The Advanced Wound Dressings segment focuses on the sale of wound and skin care products. The Biologics segment represents a new segment covering the sale of tissue-based products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.

Coloplast Finance B.V. - Post-stabilisation Period Announcement

Coloplast announces the successful issuance of EUR 2.2 billion senior notes under its Euro Medium Term Note programme

Announcement no. 06/2022 - Coloplast announces the successful issuance of EUR 2.2 billion senior notes under its Euro Medium Term Note programme

Coloplast Finance B.V. - Pre-stabilisation Period Announcement

NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES. NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON IN ANY JURISDICTION WHERE RELEASE, PUBLICATION OR DISTRIBUTION TO SUCH PERSON IS RESTRICTED BY ANY LAW OR REGULATION APPLICABLE IN SUCH JURISDICTION.

Announcement no. 05/2022 - Coloplast announces the establishment of its Euro Medium Term Note programme

Coloplast A/S (OTCPK:CLPBF) Q1 2022 Earnings Conference Call May 5, 2022 9:00 AM ET Company Participants Kristian Villumsen - President & Chief Executive Officer Anders Lonning-Skovgaard - Executive Vice President & Chief Financial Officer Conference Call Participants Hassan Al-Wakeel - Barclays Patrick Wood - Bank of America Christian Ryom - Danske Bank Graham Doyle - UBS Oliver Metzger - ODDO Niels Leth - Carnegie Craig Mcdowell - JPMorgan Yiwei Zhou - SEB Kate Kalashnikova - Citi Sam England - Berenberg Kristian Villumsen Thank you, operator. Good afternoon and welcome to our half year 2021/2022 conference call.

Coloplast A/S (CLPBF) CEO Kristian Villumsen on Q2 2022 Results - Earnings Call Transcript

News for Coloplast A/S Stock (CLPBY)